- The Innovative Cationic Emulsion for the Treatment of Dry Eye Symptoms
- An optimal Solution for Patients
- The First Product Developed From its Pipeline to be Marketed
Evry (ANTARA News/PRNewswire-AsiaNet) - Novagali Pharma, an ophthalmic specialty pharmaceutical company announces the commercial launch in France of its first product Cationorm(R). This cationic emulsion is an innovative approach to treat dry eye symptoms. It has been developed on the basis of Novagali Pharma patented technology platform Novasorb(R).
Dry eye syndrome is the second cause of consultation in ophthalmology. It concerns over 100 million people in the world and 14% of the adults of more than 40 years. Due to a chronic lack of lubrication and moisture in the eye, its consequences range from irritation to ocular inflammation of the conjunctiva and corneal tissues of the eyes. People with dry eye have sandy-gritty irritation or burning in their eyes. In most severe cases, corneal lesions may lead to vision loss. Specific factors such as ageing populations, pollution, air conditioning, extended use of computers, contribute to an increase in the prevalence of the syndrome and in opportunities for the development of more efficient products.
Cationorm(R) brings a true innovation to the patients suffering from dry eye symptoms. The cationic emulsion reproduces the tear mechanisms of action to act on the different levels of the tear film. Cationorm(R) uniquely combines lubricating and hydrating properties, optimal spreading on the surface of the eye, replenishment of the tear film lipid layer and prevention of tear evaporation. The results of clinical study have clearly demonstrated Cationorm(R) advantages for patients: tolerance, long-lasting relief and optimal comfort.
These advantages are based on Novasorb(R), the proprietary cationic emulsion technology platform of Novagali Pharma.
Novasorb(R) is designed to improve topical administration of ophthalmic medicines. It is based on the electrostatic attraction that occurs between the droplets of a positively-charged emulsion and the negatively charged cells of the ocular surface, including cornea and conjunctiva.
The commercial launch of Cationorm(R) in Europe and in the United States by the end 2008, where the product complies with the OTC status, is a major event for the development of Novagali Pharma. "Cationorm(R) commercial launch is very special to us being our first marketed product coming out of our pipeline. It is the result of many years of work for the entire Novagali team and we are very proud of the innovation Cationorm(R) brings for the treatment of dry eye symptoms," said Jerome Martinez, CEO of Novagali Pharma.
Cationorm(R) is a medical device available in France since April 2008. The product is unpreserved and packaged in box of 30 sterile single vials.
About Novagali Pharma : http://www.novagali.com
Novagali Pharma is an ophthalmic pharmaceutical company based in the Genopole biocluster in Evry (France) that develops and commercializes innovative products. Thanks to its proprietary technology platforms Novasorb(R) and Eyeject(R), the company has developed a broad pipeline of 7 innovative products addressing main ocular conditions as well as orphan diseases. Most advanced products include Vekacia(R), an orphan product for treatment of vernal keratoconjunctivitis, Cyclokat(R), a product for the treatment of moderate-to-severe dry eye syndrome and Cortiject(R) for the treatment of diabetic retinopathies. Cationorm(R), indicated for dry eye symptoms is commercialized in France since April 2008. Founded in 2000, Novagali Pharma has 50 employees.
SOURCE: Novagali Pharma
CONTACT: Presse,
Novagali Pharma,
VP RH & Communication,
Genevieve Garrigos,
+33-6-65-54-60-19,
Ariane Pretre,
genevieve.garrigos@novagali.com;
Euro RSCG,
+33-6-81-37-72-48,
ariane.pretre@eurorscg.fr;
C&O Euro RSCG C&O,
Emilie Dhelens,
+33-1-58-47-95-62,
emilie.dhelens@eurorscg.fr
Web site: http://www.novagali.com
- An optimal Solution for Patients
- The First Product Developed From its Pipeline to be Marketed
Evry (ANTARA News/PRNewswire-AsiaNet) - Novagali Pharma, an ophthalmic specialty pharmaceutical company announces the commercial launch in France of its first product Cationorm(R). This cationic emulsion is an innovative approach to treat dry eye symptoms. It has been developed on the basis of Novagali Pharma patented technology platform Novasorb(R).
Dry eye syndrome is the second cause of consultation in ophthalmology. It concerns over 100 million people in the world and 14% of the adults of more than 40 years. Due to a chronic lack of lubrication and moisture in the eye, its consequences range from irritation to ocular inflammation of the conjunctiva and corneal tissues of the eyes. People with dry eye have sandy-gritty irritation or burning in their eyes. In most severe cases, corneal lesions may lead to vision loss. Specific factors such as ageing populations, pollution, air conditioning, extended use of computers, contribute to an increase in the prevalence of the syndrome and in opportunities for the development of more efficient products.
Cationorm(R) brings a true innovation to the patients suffering from dry eye symptoms. The cationic emulsion reproduces the tear mechanisms of action to act on the different levels of the tear film. Cationorm(R) uniquely combines lubricating and hydrating properties, optimal spreading on the surface of the eye, replenishment of the tear film lipid layer and prevention of tear evaporation. The results of clinical study have clearly demonstrated Cationorm(R) advantages for patients: tolerance, long-lasting relief and optimal comfort.
These advantages are based on Novasorb(R), the proprietary cationic emulsion technology platform of Novagali Pharma.
Novasorb(R) is designed to improve topical administration of ophthalmic medicines. It is based on the electrostatic attraction that occurs between the droplets of a positively-charged emulsion and the negatively charged cells of the ocular surface, including cornea and conjunctiva.
The commercial launch of Cationorm(R) in Europe and in the United States by the end 2008, where the product complies with the OTC status, is a major event for the development of Novagali Pharma. "Cationorm(R) commercial launch is very special to us being our first marketed product coming out of our pipeline. It is the result of many years of work for the entire Novagali team and we are very proud of the innovation Cationorm(R) brings for the treatment of dry eye symptoms," said Jerome Martinez, CEO of Novagali Pharma.
Cationorm(R) is a medical device available in France since April 2008. The product is unpreserved and packaged in box of 30 sterile single vials.
About Novagali Pharma : http://www.novagali.com
Novagali Pharma is an ophthalmic pharmaceutical company based in the Genopole biocluster in Evry (France) that develops and commercializes innovative products. Thanks to its proprietary technology platforms Novasorb(R) and Eyeject(R), the company has developed a broad pipeline of 7 innovative products addressing main ocular conditions as well as orphan diseases. Most advanced products include Vekacia(R), an orphan product for treatment of vernal keratoconjunctivitis, Cyclokat(R), a product for the treatment of moderate-to-severe dry eye syndrome and Cortiject(R) for the treatment of diabetic retinopathies. Cationorm(R), indicated for dry eye symptoms is commercialized in France since April 2008. Founded in 2000, Novagali Pharma has 50 employees.
SOURCE: Novagali Pharma
CONTACT: Presse,
Novagali Pharma,
VP RH & Communication,
Genevieve Garrigos,
+33-6-65-54-60-19,
Ariane Pretre,
genevieve.garrigos@novagali.com;
Euro RSCG,
+33-6-81-37-72-48,
ariane.pretre@eurorscg.fr;
C&O Euro RSCG C&O,
Emilie Dhelens,
+33-1-58-47-95-62,
emilie.dhelens@eurorscg.fr
Web site: http://www.novagali.com
COPYRIGHT © 2008
No comments:
Post a Comment